SABCS: T-DM1 Cuts Recurrent Invasive HER2+ Breast CA Risk
Risk reduced with trastuzumab emtansine in those with residual invasive dz at sx after neoadjuvant chemo
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.